Sysmex (OTCMKTS:SSMXY) Reaches New 1-Year Low - Should You Sell?

Key Points

• Sysmex Corporation's stock reached a new 52-week low of $13.46 amid trading, significantly below its fifty-day moving average of $16.52.
• In its latest earnings report, Sysmex posted earnings per share of $0.05, falling short of analysts' expectations of $0.12, with revenue also below projections.
• The company's market capitalization stands at $8.46 billion, with a current ratio of 2.97, indicating robust short-term financial health despite recent stock performance challenges.

Sysmex Corporation ADR (OTCMKTS:SSMXY - Get Free Report) hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $13.46 and last traded at $13.46, with a volume of 7733 shares trading hands. The stock had previously closed at $13.82.

Sysmex Stock Performance

The business's fifty day moving average price is $16.52 and its two-hundred day moving average price is $17.66. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.30 and a current ratio of 2.97. The stock has a market capitalization of $8.46 billion, a P/E ratio of 26.88 and a beta of 1.15.

Sysmex (OTCMKTS:SSMXY - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.05 earnings per share for the quarter, missing analysts' consensus estimates of $0.12 by ($0.07). Sysmex had a return on equity of 10.36% and a net margin of 9.35%. The business had revenue of $717.09 million during the quarter, compared to the consensus estimate of $807.27 million. As a group, sell-side analysts forecast that Sysmex Corporation ADR will post 0.57 earnings per share for the current year.

Sysmex Company Profile

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.